Affixus Nail System for Broken Arm
Trial Summary
What is the purpose of this trial?
A commercially available product clinical study which aims to confirm the safety, performance and clinical benefits to the patient of the Affixus Natural Nail upper arm (humerus) bone nail system for both the implant itself and the instrumentation used during surgery.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the Affixus Nail System treatment for broken arms?
Is the Affixus Nail System generally safe for use in humans?
What makes the Affixus Nail System treatment unique for broken arm treatment?
The Affixus Nail System is unique because it uses an intramedullary (inside the bone) interlocking mechanism to stabilize fractures, which can be less invasive compared to traditional methods. This system is designed to provide stability without the need for the nail to jam into the bone, potentially reducing complications associated with other treatments.126810
Research Team
Hassan Achakri, Ph.D.
Principal Investigator
Director Clinical Affairs
Eligibility Criteria
This trial is for adults over 18 with a broken upper arm bone needing surgery, who can follow the study's procedures and have agreed to participate. It's not for those with certain bone conditions, infections, mental or neurologic issues that prevent consent, pregnancy, or if they're unlikely to complete the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo surgery for the implantation of the Affixus Natural Nail System Humeral Nail
Follow-up
Participants are monitored for safety, performance, and clinical benefits, including bone union, functional outcomes, and adverse events
Treatment Details
Interventions
- Affixus Natural Nail System
Affixus Natural Nail System is already approved in United States, European Union for the following indications:
- Proximal fractures (proximal short and long nails only)
- Diaphyseal fractures (proximal long, antegrade/retrograde nails)
- Open and closed fractures
- Comminuted fractures
- Nonunions and malunions
- Pathologic fractures
- Proximal fractures (proximal short and long nails only)
- Diaphyseal fractures (proximal long, antegrade/retrograde nails)
- Open and closed fractures
- Comminuted fractures
- Nonunions and malunions
- Pathologic fractures
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zimmer Biomet
Lead Sponsor
Dr. Nitin Goyal
Zimmer Biomet
Chief Medical Officer since 2021
MD from Harvard Medical School
Ivan Tornos
Zimmer Biomet
Chief Executive Officer since 2023
MBA from the University of Miami School of Business, BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business